Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PKPD study of IV-administered Tobramycin in children with cystic fibrosis

ABSTRACT: PKPD study of IV-administered Tobramycin in children with cystic fibrosis

PROVIDER: PRJEB81247 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13866000_1.fastq.gz	Fastqsanger.gz
	ERR13866000_2.fastq.gz	Fastqsanger.gz
	ERR13866001_1.fastq.gz	Fastqsanger.gz
	ERR13866001_2.fastq.gz	Fastqsanger.gz
	ERR13866002_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 148

Similar Datasets

Tobramycin Treatment of Planktonic Pseudomonas aeruginosa

2008-06-10 | GSE9991 | GEO

Identification of adaptive mechanisms leading to reduced antibiotic susceptibility in bacterial biofilms using experimental evolution. Part 3: Pseudomonas aeruginosa floating biofilms in synthetic cystic fibrosis medium

Project description:Pseudomonas aeruginosa was repeatedly and intermittently exposed to tobramycin. Bacteria were grown in synthetic cystic fibrosis medium in wells of a 96-well microtiter plate. After 24 hours, more medium with or without tobramycin was added. After another 24 hours of incubation, a subsample of the well content was used to inoculate fresh synthetic cystic fibrosis medium in a 96-well microtiter plate. This was repeated for a total of 15 cycles. Evolved lineages were then DNA-sequenced to screen for genome changes.

2022-08-18 | E-MTAB-11894 | biostudies-arrayexpress

Transcription profiling of planktonic pseudomonas aeruginosa exposed to tobramycin treatment

Project description:As a comparison to tobramycin-treated P. aeruginosa biofilms, we investigated the response of planktonic P. aeruginosa to tobramycin by microarray. Experiment Overall Design: We included 2 control (untreated) cultures and 2 tobramycin-treated cultures. We used mid-exponential phase cultures of P. aeruginosa PA14. Replicate cultures were incubated in the presence or absence of 5 Î¼g/mL tobramycin for 30 minutes at 37Â°C.

2008-06-21 | E-GEOD-9991 | biostudies-arrayexpress

Kristen-PAO1-anaerobic lethal concentrations tobramycin

Project description:To see the effects of tobramycin on Pseudomonas aeruginosa under anaerboc lethal conditions. RNA was isolated from 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 and 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 after being treated with 20 ug/ml tobramycin for 30 minutes.

2011-01-20 | E-FPMI-24 | biostudies-arrayexpress

Plasma microRNA levels in male and female children with cystic fibrosis

Project description:A gender gap exists in cystic fibrosis (CF). Here we investigate whether plasma microRNA expression profiles differ between the sexes in CF children. microRNA expression was quantified in paediatric CF plasma (n=12; six females; Age range:1-6; Median Age: 3; 9 Phe508del homo- or heterozygotes) using TaqMan OpenArray Human miRNA Panels. Principal component analysis indicated differences in male versus female miRNA profiles. The miRNA array analysis revealed two miRNAs which were significantly increased in the female samples (miR-885-5p; fold change (FC):5.07, adjusted p value: 0.026 and miR-193a-5p; FC:2.6, adjusted p value: 0.031), although only miR-885-5p was validated as increased in females using specific qPCR assay (p < 0.0001). Gene ontology analysis of miR-885-5p validated targets identified cell migration, motility and fibrosis as processes potentially affected, with RAC1-mediated signalling featuring significantly. There is a significant increase in miR-885-5p in plasma of females versus males with CF under six years of age.

2020-10-27 | GSE132106 | GEO

Transcription profiling of Pseudomonas aeruginosa treated with tobramycin

Project description:This SuperSeries is composed of the following subset Series:; GSE9989: Tobramycin Treatment of P. aeruginosa Biofilms Grown on CFBE41o- Cells; GSE9991: Tobramycin Treatment of Planktonic Pseudomonas aeruginosa Experiment Overall Design: Refer to individual Series

2008-06-18 | E-GEOD-10030 | biostudies-arrayexpress

Early microbiota dysbiosis and intestinal inflammation in children with cystic fibrosis

Project description:Early microbiota dysbiosis and intestinal inflammation in children with cystic fibrosis

| PRJEB28609 | ENA

Plasma microRNA levels in male and female children with cystic fibrosis

Project description:Plasma microRNA levels in male and female children with cystic fibrosis

| PRJNA545954 | ENA

Kristen-PAO1 aerobic sub-inhibitory cond. tobramycin

Project description:To see the effect of sub-inhibitory concentrations of tobramycin on Pseudomonas aeruginosa grown under aerobic conditions. RNA was isolated form 4 biological repeats of P.aeruginosa grown to mid-log in cationic adjusted mueller hinton broth and 4 biological repeats of P.aeruginosa with the addition of 0.25ug/ml tobramycin in cationic adjusted mueller hinton broth. null

2011-03-30 | E-FPMI-23 | biostudies-arrayexpress

Identification of potential tobramycin-resistant mutagenesis of Escherichia coli strains after spaceflight

Project description:Background: This study aimed to explore potential tobramycin-resistant mutagenesis of Escherichia coli (E. coli) strains after spaceflight. Methods: A spaceflight-induced mutagenesis of multi-drug resistant E.coli strain (T1_13) on the outer space for 64 days (ST5), and a ground laboratory with the same conditions (GT5) were conducted. Both whole-genome sequencing and RNA-sequencing were performed. Results: A total of 75 SNPs and 20 InDels were found to be associated with the resistance mechanism. Compared to T1_13, 1242 genes were differentially expressed in more than 20 of 38 tobramycin-resistant E. coli isolates while not in GT5. Function annotation of these SNPs/InDels related genes and differentially expressed genes was performed. Conclusion: This study provided clues for potential tobramycin-resistant spaceflight-induced mutagenesis of E. coli.

2019-12-13 | GSE123795 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data